Conditions: Ovarian Cancer
Keywords: ZD6474 Vandetanib Zactima Ovarian Cancer Phase I Phase II Randomized Safety
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or peritoneum. A total of approximately 5 national centers will participate in phase I of the study. If the starting criteria for phase II of the study are met at the end of phase I, a total of approximately 20 national centers will participate in phase II of the study.

Detailed description:

Arms:
arm 1: Vandetanib added to standard therapy (pegliposomal doxorubicin)

Interventions: intervention 1: Vandetanib
Intervention descriptions: intervention 1: 100mg doses orally, once daily

Protocol document: